UroGen Pharma (URGN) Capital Expenditures (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Capital Expenditures data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Capital Expenditures rose 1169.72% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 1079.64% YoY) and the FY2025 annual result came in at $4.6 million, up 415.53% from the prior year.
• Capital Expenditures advanced to $2.3 million in Q1 2026, from -$1.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $6.0 million in Q3 2025 to a low of -$1.6 million in Q4 2025.
• A 5-year average of $354235.3 and a median of $169000.0 in 2022 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 2066.34% in 2025, down 829.68% in 2025.
• Tracing URGN's Capital Expenditures over 5 years: stood at $269000.0 in 2022, then slumped by 104.46% to -$12000.0 in 2023, then jumped by 1925.0% to $219000.0 in 2024, then plunged by 829.68% to -$1.6 million in 2025, then soared by 245.93% to $2.3 million in 2026.
• The last three Capital Expenditures figures came in at $2.3 million (Q1 2026), -$1.6 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.